Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Dutasteride can significantly increase libido, more so than finasteride. Users reported higher libido when switching from finasteride to dutasteride.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

A user is treating hair loss with 0.5mg Dutasteride three times a week, 5mg oral Minoxidil daily, and topical finasteride and minoxidil, seeing some improvement but insufficient density. They are considering increasing Dutasteride dosage and addressing high estradiol levels, while also trying to quit vaping.

Significant hair regrowth was achieved after 4.5 months using 0.5 mg Dutasteride and 5 mg oral Minoxidil. Tips on obtaining prescriptions and discussions on effectiveness and side effects were also shared.

Using PRP or Exosome treatments alongside Finasteride/Dutasteride and Minoxidil may not significantly enhance results. Dutasteride and oral Minoxidil are considered more effective options.

Oral Minoxidil can cause puffy eyes and fluid retention. Adding an ACE inhibitor or ARB, like Telmisartan, may help mitigate these side effects.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user experienced significant hair growth using 0.5 mg Dutasteride and 5 mg oral Minoxidil over 10 weeks, with initial shedding but no side effects. The treatment was surprisingly affordable at $7 for a 3-month supply.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

A user with kidney disease and high blood pressure experienced hair thinning, especially around the vertex. They are currently using finasteride and oral minoxidil but are considering whether to resume blood pressure medication despite managing symptoms with diet and exercise.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The user experienced hair recovery using oral dutasteride 0.5 mg and oral minoxidil 5 mg daily, considering increasing dutasteride dosage but concerned about cost and effectiveness. They noted progress and discussed alternatives like hair transplants and other medications.

A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.

The user is considering switching from Minoxidil to dutasteride for hair loss treatment but is concerned about the potential for increased shedding. They are seeking advice on whether to wait for the current shedding phase to subside before starting dutasteride.

The conversation discusses purchasing Avodart (dutasteride) at a low price, with the OP using 1mg daily for hair loss. Users inquire about the source, and OP confirms buying from Oxford Pharmacy in the UK.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

A 20-year-old used finasteride for 5 months, then switched to dutasteride for 7 months, and added oral minoxidil for 2.5 months, finding the combination of dutasteride and oral minoxidil most effective. The user experienced significant hair improvement and confidence boost, with no blood tests but an ECG to monitor heart health.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

A user experienced hair retention but sexual side effects after using dutasteride for a year. Others shared similar experiences with finasteride and dutasteride, suggesting consulting a doctor for persistent issues.

Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.

A user is seeking recommendations for doctors who perform Dutasteride mesotherapy in NJ or PA, as they are having trouble finding one through Google. The conversation focuses on finding a suitable provider for this specific hair loss treatment.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Higher doses of dutasteride, like 2.5 mg, may offer more hair growth than 0.5 mg, but the difference is not significant for most people. Many users find 0.5 mg effective, and increasing the dose is often unnecessary unless experiencing severe hair loss.

A user is experiencing worsening hair loss despite using 2.5mg Dutasteride, RU58841, and Minoxidil daily for over 8 months. They are concerned that daily nicotine from vaping might be counteracting the treatments.

A 43-year-old experienced gynecomastia after 20 years of taking dutasteride and 7.5mg oral minoxidil. Suggestions include consulting an endocrinologist, checking hormones, and considering Nolvadex or DIM supplements.